en

Kinase


Product Name: Format/Size Descriptions Download
Kinase Library 6084 compounds
For cherry-picking
Update: 2020-07
ASINEX facilitates the discovery of novel kinase inhibitors by providing access to our advanced collection of small molecules, fragments and macrocycles. The efficacy of our compounds has been validated through in silico modeling and in vitro on-target and phenotypic profiling. This is paralleled with 20+ years of medicinal chemistry expertise, delivering designs with outstanding ADMET and PK properties, optimizing chances in hit to candidate development. F
Kinase Type II Inhibitors 2376 compounds
For cherry-picking
Update: 2020-07
ASINEX has designed molecules that could act as Type-II Kinase ligands using a proprietary computational algorithm.
SL#015
Ser-Thr Kinases
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has designed molecules that in vitro target a number of Ser-Thr Kinases including Aurora A, Aurora B, Haspin, and B-Raf.
SL#026
IRAK4 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has created a series of IRAK4-oriented compounds by combining the IRAK4 hinge binding motif with proprietary natural product-like fragments. Several compounds from this library were screened against IRAK4 kinase in vitro and showed sub-uM IC50. Sunitinib was also included in the library as a reference compound.
SL#046
EGFR, PDGFR alpha & beta inhibitors
80 compounds
Pre-Plated Set
Release: 2016
Screening of the ASINEX BioDesign Libraries has revealed a number of potent (IC50 < 1µM) inhibitors of EGFR and PDGFRɑ/β . This library is a useful starting point for kinase-oriented research and drug discovery.
SL#073
CNS Kinase - DLK (MAP3K12)
80 compounds
Pre-Plated Set
Release: 2017
80 analogs of the reported hits have been included in this library.
SL#074
PKCε translocation inhibitors
80 compounds
Pre-Plated Set
Release: 2017
ATP-competitive inhibitors of the PKC family show a lack of desired selectivity. In order to identify a selective inhibitor of PKCε signaling, research pointed to a molecule that can disrupt the PKCε/RACK2 interaction.
A series of thienoquinolines was shown to prevent the PKCε/RACK2 interaction at low uM concentrations. Initial hits originated from the Asinex collections; analogs of the reported hits were included in this library.
SL#082
p38 Inhibitors for
anti-Inflammatory Drug Discovery
80 compounds
Pre-Plated Set
Release: 2018
A number of natural product and synthetic inhibitors of p38 kinase family has been reported showing a promising anti-inflammatory activity in several models. However, low specificity, low efficacy, and high toxicity of known candidates, creates an unmet need for novel agents.
Using a proprietary library design platform ASINEX has created molecules that in vitro target p38a in a range of therapeutically relevant concentrations.
Contact
Global

Ludmila Sadovenko

lsadovenko@asinex.com
North America

Mark Parisi

mparisi@asinex.com

Toll Free: +1 877 ASINEX1

Tel: +1 336 721 1617

Fax: +1 336 721 1618

N.Chestnut St., Ste.104

Winston-Salem, NC 27101

USA

Europe

Galina Afanasyeva

gafanasyeva@asinex.com

Tel: +31 (0) 203416183

Klaprozenweg 75C, 1033NN

Amsterdam, The Netherlands

Japan

Shingo Ota

sota@asinex.com

Tel: 080-3401-9097

30-2 Higashihazu, Nishio,

Aichi Japan

Cart
Your cart is empty
Order
$
0
Checkout
Thanks for your order
We will contact you shortly